Cited by 561MicroRNA in disease regulationCancer-related Molecular PathwaysCancer-related molecular mechanisms research

MicroRNAs in the miR-106b family regulate p21/CDKN1A and promote cell cycle progression

Open access
Ivanovska, Irena, Ball, Alexey S., Diaz, Robert L., Magnus, Jill F., Kibukawa, Miho, Schelter, Janell M., Kobayashi, Sumire V., Lim, Lee +4 more·2008·Molecular and Cellular Biology

Abstract

microRNAs in the miR-106b family are overexpressed in multiple tumor types and are correlated with the expression of genes that regulate the cell cycle. Consistent with these observations, miR-106b family gain of function promotes cell cycle progression, whereas loss of function reverses this phenotype. Microarray profiling uncovers multiple targets of the family, including the cyclin-dependent kinase inhibitor p21/CDKN1A. We show that p21 is a direct target of miR-106b and that its silencing plays a key role in miR-106b-induced cell cycle phenotypes. We also show that miR-106b overrides a doxorubicin-induced DNA damage checkpoint. Thus, miR-106b family members contribute to tumor cell proliferation in part by regulating cell cycle progression and by modulating checkpoint functions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mcb.01977-07

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • miR-106b targets several genes implicated in cell cycles, such as p21, E2F, TAF5-like RNA polymerase II, and PTEN.

    “Previous studies have shown that miR-106b targets several genes implicated in cell cycles, such as cyclin-dependent kinase inhibitor 1A (p21), E2F transcription factor, TAF5-like RNA polymerase II, and phosphatase and tensin homolog (Ivanovska et al., 2008; Pichiorri et al., 2008; Poliseno et al., 2010; Trompeter et al., 2011).”

    From miR-106b impairs cholesterol efflux and increases Aβ levels by repressing ABCA1 expression (2012) · cites this paper as Ivanovska et al., 2008

    The Results identify p21/CDKN1A as a direct miR-106b target and report other likely cell-cycle-related targets. They do not identify TAF5-like RNA polymerase II or PTEN as targets; E2F appears in the references, but the Results say previously identified single targets were not regulated in this experimental system. Because the citations are not assigned to individual genes, this source supports only part of the cited list. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [5]Bunz, F., A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler, and B. Vogelstein. 1998. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 2821497-1501. [DOI] [PubMed] [Google Scholar]

Cited by

Sorted by citations

Authors
Ivanovska, I., Ball, A. S., Diaz, R. L., Magnus, J. F., Kibukawa, M., Schelter, J. M., Kobayashi, S. V., Lim, L., Burchard, J., Jackson, A. L., Linsley, P. S., & Cleary, M. A.
Affiliations
Rosetta Inpharmatics LLC, Seattle, Washington 98109
Corresponding author
Ivanovska, Irena
Venue
Molecular and Cellular Biology
Published
2008-04-01
Volume
28
Issue
7
Pages
2167-2174
ISSN
  • 0270-7306 (ISSN-L)
  • 1098-5549
OpenAlex
W2100975741
Cited by
561
References
52
Citations by year
2026: 6 · 2025: 7 · 2024: 9 · 2023: 13 · 2022: 9 · 2021: 17 · 2020: 19 · 2019: 26 · 2018: 25 · 2017: 21 · 2016: 32 · 2015: 37 · 2014: 52 · 2013: 58 · 2012: 53
FWCI
20.04
Type
journal article
Language
en
Open access
Locations
  • Molecular and Cellular Biology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
microRNA, CDKN1A/p21, cell cycle progression, cyclin-dependent kinase inhibitors, microRNA target regulation, tumor cell proliferation
MeSH terms
Breast, Cell Cycle, Cell Line, Transformed, DNA Damage, Doxorubicin, Female, Humans, Neoplasm Proteins, RNA, Messenger, RNA, Neoplasm, Genes, cdc, RNA Interference, RNA, Small Interfering, MicroRNAs, Cyclin-Dependent Kinase Inhibitor p21

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review